rs121918677
Variant summary
Our verdict is Benign. Variant got -16 ACMG points: 0P and 16B. BP4_StrongBP6_Very_StrongBS2
The NM_001063.4(TF):c.2012G>A(p.Gly671Glu) variant causes a missense change. The variant allele was found at a frequency of 0.00385 in 1,614,010 control chromosomes in the GnomAD database, including 17 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Likely benign (★★). Another nucleotide change resulting in same amino acid change has been previously reported as Likely benignin UniProt.
Frequency
Consequence
NM_001063.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Benign. Variant got -16 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
TF | NM_001063.4 | c.2012G>A | p.Gly671Glu | missense_variant | 16/17 | ENST00000402696.9 | |
TF | NM_001354703.2 | c.1880G>A | p.Gly627Glu | missense_variant | 22/23 | ||
TF | NM_001354704.2 | c.1631G>A | p.Gly544Glu | missense_variant | 15/16 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
TF | ENST00000402696.9 | c.2012G>A | p.Gly671Glu | missense_variant | 16/17 | 1 | NM_001063.4 | P1 | |
TF | ENST00000467842.1 | n.3006G>A | non_coding_transcript_exon_variant | 2/2 | 1 | ||||
TF | ENST00000461695.1 | c.*312G>A | 3_prime_UTR_variant, NMD_transcript_variant | 6/7 | 3 |
Frequencies
GnomAD3 genomes AF: 0.00294 AC: 448AN: 152164Hom.: 3 Cov.: 32
GnomAD3 exomes AF: 0.00251 AC: 630AN: 251236Hom.: 0 AF XY: 0.00260 AC XY: 353AN XY: 135816
GnomAD4 exome AF: 0.00395 AC: 5772AN: 1461728Hom.: 14 Cov.: 31 AF XY: 0.00387 AC XY: 2813AN XY: 727192
GnomAD4 genome AF: 0.00294 AC: 448AN: 152282Hom.: 3 Cov.: 32 AF XY: 0.00255 AC XY: 190AN XY: 74472
ClinVar
Submissions by phenotype
Atransferrinemia Benign:2
Likely benign, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Jan 13, 2018 | This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score and internal cut-off values, a variant classified as likely benign is not then subjected to further curation. The score for this variant resulted in a classification of likely benign for this disease. - |
Likely benign, criteria provided, single submitter | clinical testing | Mendelics | Dec 31, 2023 | - - |
not provided Benign:2
Likely benign, criteria provided, single submitter | clinical testing | Invitae | Feb 01, 2024 | - - |
Likely benign, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Apr 01, 2023 | TF: BS1 - |
Transferrin variant B2 Pathogenic:1
Pathogenic, flagged submission | literature only | OMIM | May 01, 1984 | - - |
not specified Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Feb 15, 2023 | Variant summary: TF c.2012G>A (p.Gly671Glu) results in a non-conservative amino acid change located in the Transferrin-like domain of the encoded protein sequence. Four of four in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 0.0025 in 251236 control chromosomes. The observed variant frequency is approximately 2.24 fold of the estimated maximal expected allele frequency for a pathogenic variant in TF causing Atransferrinemia phenotype (0.0011), strongly suggesting that the variant is benign. c.2012G>A has been reported in the literature, without strong evidence for causality. These reports do not provide unequivocal conclusions about association of the variant with Atransferrinemia. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Three clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. Two submitters classified the variant as likely benign while one classified as pathogneic. Based on the evidence outlined above, the variant was classified as likely benign. - |
TF-related disorder Benign:1
Likely benign, criteria provided, single submitter | clinical testing | PreventionGenetics, part of Exact Sciences | Jan 26, 2024 | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at